ESC 365 - Interactive question and answer session - PCSK9 inhibition to prevent and treat atherosclerotic cardiovascular disease.

ESC Premium Access

Interactive question and answer session - PCSK9 inhibition to prevent and treat atherosclerotic cardiovascular disease.

Session: PCSK9 inhibition to prevent and treat atherosclerotic cardiovascular disease

Topic: Lipids

Speaker: Professor D. Bhatt (New York City, US)

Sponsored by Sanofi US and Regeneron Pharmaceuticals

Event: ESC Congress 2018

Congress Presentation

About the speaker

Professor Deepak Bhatt

Mount Sinai Hospital, New York City (United States of America)

36 presentations

4 followers

4 more presentations in this session

Chairman’s welcome and introduction: the mandate for improving residual cardiovascular disease risk reduction in patients with adversely elevated LDL-C

Speaker: Professor D. Bhatt (New York City, US)

What do recent landmark, cardiovascular outcome trials evaluating PCSK9 inhibition in high risk patient populations teach us?

Speaker: Professor P. Steg (Paris, FR)

Guidelines and the role of non-statin therapies for ASCVD reduction in high risk patients - Addressing statin intolerance and poor target LDL-C goal attainment

Speaker: Professor J. Jukema (Leiden, NL)

Getting real world and “hands on” in patients with elevated LDL-C and high risk features for atherosclerotic cardiovascular disease — Case management sessions.

Speaker: Professor D. Bhatt (New York City, US)

Access the full session

PCSK9 inhibition to prevent and treat atherosclerotic cardiovascular disease

Speakers: Professor D. Bhatt, Professor D. Bhatt, Professor P. Steg, Professor J. Jukema, Professor D. Bhatt

About the event

ESC Congress 2018

7 November - 29 August 2018

Sessions Presentations

Congress

ESC 365 is supported by